CTOs on the Move


 
Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company`s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra`s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.lyndra.com
  • 65 Grove Street Suite 301
    Watertown, MA USA 02472
  • Phone: 857.201.5314

Executives

Name Title Contact Details
Jacqueline Fernandes
Vice President of Data Compliance and Information Technology Profile
Kyle Haraldsen
Chief Technology Officer Profile
Orn Almarsson
Chief Technology Officer Profile

Funding

Lyndra raised $23M on 04/13/2017
Lyndra raised $55M on 01/29/2019
Lyndra raised $13M on 07/30/2019

Similar Companies

Metrohm USA Inc

Metrohm USA Inc is a Riverview, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VLST

VLST is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CorneaGen

CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea.

Dyno Therapeutics

Dynotx.com provides cutting-edge sales and marketing tools for small and medium-sized businesses. Their services include web design, social media management, advertising, and SEO optimization. They aim to help businesses grow and succeed online by prov...

Talaris Therapeutics

Talaris Therapeutics is a late-clinical stage biotechnology company based in Boston, MA and Louisville, KY. Talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. The company was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA.